Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00050076 | Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure. | PHASE2 | COMPLETED | 204 | — | — | Aug 1, 2002 | Aug 1, 2003 | Feb 2, 2012 | 53 | United States |
| Arm | Type | Description |
|---|---|---|
| MCC-135 50 mg BID | EXPERIMENTAL | - |
| MCC-135 100 mg QD | EXPERIMENTAL | - |
| MCC-135 200 mg QD | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MCC-135 | DRUG | MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks |
| Placebo | DRUG | MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks |
Inclusion: * Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. * Having a clinical diagnosis consistent with congestive heart failure, of at least 6 month...